Consumer Information On Bontril

Bontril (phendimetrazine tartrate) has the chemical name of (+)-3,4-Dimethyl-2-phenylmorpholine Tartrate.

Although it is used for the treatment of obesity, it may have certain risk factors that are essential to be considered before prescribing the drug. This drug should not be used by the pregnant women until and unless it is advised by the doctors to take it for such potential benefits that overcome the possible hazards.

Bontril is a Schedule III controlled substance. This drug has chemical and pharmacological relation with the amphetamines. There is a need to keep in mind the chances of abuse to occur due to phendimetrazine when it is prescribed because it has been found that extensive abuse of amphetamines and the related stimulant drugs has occurred.

There may be association between the abuse of amphetamines and the related stimulant drugs with severe social dysfunction and intense psychological dependence. Due to its amphetamines nature, it is has been reported many times that the patients had increased their dosage to many times that had been originally prescribed by their doctor. If prolonged high dosage of the drug is terminated abruptly, it is found that such patients get involved in mental depression and extreme fatigue.

Changes have occurred in the sleep EEG. There are always chances for the signs of chronic intoxication due to anorectic drugs. The signs of chronic intoxication include marked insomnia, hyper activity, personality changes, severe dermatoses and irritability.

The most severe sign of chronic intoxication that is resulted due to the use of anorectic drugs is psychosis that is often cannot be distinguished from schizophrenia.